计算溶液所需的质量、体积或浓度。
Canakinumab (Anti-IL-1b) (Ab170512) - SEC
The purity of Canakinumab (Anti-IL-1b) (Ab170512) is more than 95% verified by HPLC.
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
Ab170512-100μg |
100μg |
期货 ![]() |
| |
Ab170512-1mg |
1mg |
现货 ![]() |
| |
Ab170512-5mg |
5mg |
现货 ![]() |
| |
Ab170512-10mg |
10mg |
期货 ![]() |
|
产品名称 | Canakinumab (Anti-IL-1b), INHIBITOR of Interleukin-1 beta inhibitor |
---|---|
英文别名 | Catabolin | IL-1 beta |
规格或纯度 | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
特异性 | IL1B |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
种属反应性 | Human,Mouse |
偶联 | Unconjugated |
作用类型 | 抑制剂 |
作用机制 | INHIBITOR of Interleukin-1 beta inhibitor |
克隆类型 | Recombinant |
---|---|
Format | Whole IgG |
亚型 | Human IgG1 |
轻链亚型 | kappa |
SDS-PAGE | 145.06 kDa |
纯化方法 | Protein A purified |
纯度 | >95% |
来源 | CHO supernatant |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | Lot by Lot |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS编号和信息 | 914613-48-2 |
Canakinumab (Anti-IL-1b) (Ab170512) - SEC
The purity of Canakinumab (Anti-IL-1b) (Ab170512) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 24-12-06 | Ab170512 |
![]() |
分析证书 | 24-12-06 | Ab170512 |
![]() |
分析证书 | 24-12-06 | Ab170512 |
![]() |
分析证书 | 24-01-18 | Ab170512 |
![]() |
分析证书 | 24-01-18 | Ab170512 |
1. Church LD, McDermott MF. (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.. Curr Opin Mol Ther, 11 (1): (81-9). [PMID:19169963] [10.1021/op500134e] |
2. Ridker PM, Lüscher TF. (2014) Anti-inflammatory therapies for cardiovascular disease.. Eur Heart J, 35 (27): (1782-91). [PMID:24864079] [10.1021/op500134e] |
3. Priestle JP, Schär HP, Grütter MG. (1989) Crystallographic refinement of interleukin 1 beta at 2.0 A resolution.. Proc Natl Acad Sci USA, 86 (24): (9667-71). [PMID:2602367] [10.1021/op500134e] |
1. Church LD, McDermott MF. (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.. Curr Opin Mol Ther, 11 (1): (81-9). [PMID:19169963] [10.1021/op500134e] |
2. Ridker PM, Lüscher TF. (2014) Anti-inflammatory therapies for cardiovascular disease.. Eur Heart J, 35 (27): (1782-91). [PMID:24864079] [10.1021/op500134e] |
3. Priestle JP, Schär HP, Grütter MG. (1989) Crystallographic refinement of interleukin 1 beta at 2.0 A resolution.. Proc Natl Acad Sci USA, 86 (24): (9667-71). [PMID:2602367] [10.1021/op500134e] |